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Abstract
Complex interventions, such as the introduction of medical
emergency teams or an early goal-directed therapy protocol, are
developed from a number of components that may act both
independently and inter-dependently. There is an emerging body of
literature advocating the use of integrated complex interventions to
optimise the treatment of critically ill patients. As with any other
treatment, complex interventions should undergo careful evaluation
prior to widespread introduction into clinical practice. During the
development of an international collaboration of researchers
investigating protocol-based approaches to the resuscitation of
patients with severe sepsis, we examined the specific issues
related to the evaluation of complex interventions. This review
outlines some of these issues. The issues specific to trials of
complex interventions that require particular attention include
determining an appropriate study population and defining current
treatments and outcomes in that population, defining the study
intervention and the treatment to be used in the control group, and
deploying the intervention in a standardised manner. The context in
which the research takes place, including existing staffing levels
and existing protocols and procedures, is crucial. We also discuss
specific details of trial execution, in particular randomization,
blinded outcome adjudication and analysis of the results, which are
key to avoiding bias in the design and interpretation of such trials.
These aspects of study design impact upon the evaluation of
complex interventions in critical care. Clinicians should also
consider these specific issues when implementing new complex
interventions into their practice.
Introduction
Management of critically ill patients is complex, involving
multiple interventions and processes. Concomitant life-
threatening pathologies require numerous and potentially
interactive therapies delivered by a variety of health-care
professionals. One simple observation exists: outcomes are
improved when care is coordinated by medical teams with
experience, training, or decision support [1-3]. Consequently,
there is an emerging body of literature advocating the use of
integrated complex interventions to optimise the treatment of
critically ill patients. Examples of these complex interventions
include medical emergency teams [4], early goal directed
therapy for the management of patients with severe sepsis
[5], educational interventions to improve compliance with
guidelines for the treatment of patients with pneumonia in the
emergency department [6] or even a bundle of measures to
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improve the management of all patients in the intensive care
unit (ICU) [7].
Complex interventions are defined as interventions or
therapies that may act both independently and inter-
dependently [8], often more than just the sum of their
components. Complex interventions may be seen as inter-
ventions where the function of the intervention remains
constant (for example, to alleviate hypoperfusion in patients
with severe sepsis), rather than the specific components (for
example, a specific resuscitation protocol, or use of a specific
fluid regime) used to achieve this function [9]. This allows
tailoring of the intervention to the context in which the
intervention is applied.
The evaluation of complex interventions requires a careful
study of all potential benefits as well as adverse effects that
could be attributed to the intervention. While observational
studies may provide insight into the effectiveness of
treatments, causal inferences require appropriately powered,
randomized controlled trials (RCTs) [10]. RCTs, however, are
typically used to test single interventions, such as the benefits
of a drug compared to placebo and although the principles
underlying the testing of a more complex intervention are the
same, particular theoretical and practical difficulties arise for
researchers conducting trials and for clinicians attempting to
critically appraise their results. These difficulties include
determining a representative study population, defining the
intervention and deploying it in a standardised manner, and
measuring appropriate outcomes.
The aim of this review is to give clinicians insight into the
process of designing trials to evaluate whether a new
complex intervention results in improved outcomes. It is
hoped that these insights will aid clinicians when they
consider implementing complex interventions into their own
practice.
Methods
The concepts and themes of this paper arose out of
discussions held between the ProCESS (Protocolized Care
for Early Septic Shock, US based trial), ARISE (Australasian
Resuscitation in Sepsis Evaluation) and ProMISe (Proto-
colised Management in Sepsis, UK based trial) investigators
during the development of their respective protocols. Each
team of investigators is planning a multi-centre RCT of a
resuscitation protocol for patients with early severe sepsis.
We augmented the expert discussions with a literature
search (Medline was searched using the PubMED interface),
using search terms for ‘complex interventions’ combined with
search terms to identify studies relevant to critical care. We
also searched the relevant epidemiological literature, and
included references pertaining to recent illustrative cases in
critical care. The themes and concepts are addressed in four
sections: pre-trial activities, trial design, trial execution, and
trial reporting, and are summarised in Table 1.
Pretrial activities
The phased development and testing of a new single
intervention (such as a monoclonal antibody for sepsis) is a
well-developed and well recognized process. In vitro testing
followed by animal studies establish a biological rationale and
provide preliminary safety data, and phase I trials in healthy
volunteers and phase II trials in subjects with the target
condition precede definitive phase III studies. When evalua-
ting a complex intervention, the pre-trial phase may follow a
different but analogous path. Frameworks for the design and
evaluation of complex interventions that outline a step-wise
approach to the research process exist [8,11]. It is important
to note that when evaluating a complex intervention, this
process may be iterative rather than linear. It may be
necessary to explore the mechanism of action of the various
components of the protocol simultaneously with an
investigation of interactions between components and an
exploration of the best methods to implement the protocol. In
comparison to the evaluation of single interventions, where
the focus is generally on addressing a question such as
whether this new monoclonal antibody for sepsis reduces
mortality, the evaluation of complex interventions may address
the question of whether this protocol for resuscitation of
patients with severe sepsis reduces mortality. Alternatively, a
complex intervention trial may ask an implementation
question: what is the optimal way to implement this protocol
for resuscitation of patients with severe sepsis?
Literature review
As with any investigation, assessing previous knowledge,
successes and difficulties must occur. This allows the
research question to be honed and avoids unintended
duplicative efforts. In the case of complex interventions,
additional aspects of the literature review are crucial. In the
case of a resuscitation protocol for patients with severe
sepsis, the review must examine the supportive evidence for
each of the component parts. There must be a rationale for
combining the components and for the choice of methods
used to educate the staff and to implement the protocol.
Knowing what, if anything, is understood about the way that
these components interact will allow an optimal design. An
understanding of the methods of organisational change may
also be important.
Retrospective studies
National databases such as the Intensive Care National Audit
and Research Case Mix Programme in the United Kingdom
[12,13] and the Australian and New Zealand Intensive Care
Society Adult Patient Database [14] provide important
information regarding the intended study population, potential
recruitment rates and baseline patient outcomes [15]. For
example, in an early sepsis resuscitation protocol trial,
knowing how many of the components of a particular
resuscitation protocol for sepsis are currently being delivered,
whether the delivery of the components of therapy within the
protocol have changed over time, and how the mortality hasPage 3 of 9
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Table 1
Comparison of the methodological issues to be considered in the evaluation of single and complex interventions in critical care
Evaluation of a single intervention
Component of  (for example, a monoclonal antibody Evaluation of a complex intervention 
the evaluation for patients with sepsis) (for example, a resuscitation protocol for patients with sepsis)
Pre-trial activities
Study question To determine whether this monoclonal  To determine whether this resuscitation protocol compared to usual care 
antibody compared to placebo reduces  reduces mortality for patients with severe sepsis
mortality for patients with severe sepsis To determine the best way to implement a new protocol for the resuscitation 
of patients with severe sepsis
Pre-clinical phase Linear approach from in vitro studies to  Non-linear, iterative approach is needed to examine the effectiveness of 
animal studies to phase I and phase II  each aspect of the protocol, how these aspects interact with current 
clinical trials practice and what methods of implementing the protocol as a whole are 
likely to be most successful
Pilot studies Focussed on feasibility of recruitment,  Will help determine feasibility of implementing the protocol as a whole, 
compliance with treatment and follow-up which components are most commonly implemented or missed
Needed to identify barriers to implementing the protocol, potential means to 
overcome these barriers, optimal strategies for implementing the protocol
Trial design
Population Will be patients with the target condition,  May be patients with the target condition, or it may be health service delivery 
for example, two SIRS criteria and  organisations. For example, attempts to determine whether the protocol 
evidence of organ dysfunction in patients  works may be focussed on patients with severe sepsis or attempts to 
with suspected or proven infection determine how best to implement the protocol may be focussed on 
physicians or even hospitals 
Intervention Clearly defined single drug therapy Will contain multiple interventions, for example, increased fluids, blood 
transfusions, vasopressors, additional monitoring devices (arterial lines, 
lactate measurements, ScvO2 measurements), as well as specific guidance 
to clinicians regarding the timing of these interventions
Comparison  Placebo The control group could receive ‘usual care’ as determined by individual 
group clinicians, a defined protocol of ‘usual care’, a protocol with different 
components, or an alternative suite of interventions (for example, 
computerised reminders) to enhance compliance with the protocol under 
investigation
Outcome Primary outcome: all cause mortality  Primary outcome may be mortality or compliance with the protocol may be 
at 90 days the primary outcome of interest. As blinding may be less than optimal, well 
defined and robust outcomes are required
Context May relate to the other treatments  Crucial element of trial design. Factors to consider include the existing 
delivered in conjunction with the  protocols in place, staffing levels (both numbers and experience), availability 
monoclonal antibody treatment. Generally  of ScvO2 monitors, resources of the emergency department and current 
reported in a table of co-interventions treatment patterns
Trial execution
Randomization Individual participants will be randomized Randomization may be at the individual participant level, particularly for trials 
designed to determine whether the protocol is effective
Randomization may also need to be at the level of the health care provider 
or service delivery organization when the aim of the study is to determine 
how best to implement the protocol
Blinding Blinding should be possible Blinding of the intervention is likely to be difficult or impossible, and may not 
be desirable if the intention is to determine the best way to implement the 
protocol. Attempts to blind outcome adjudication, data analysts may be 
possible and will enhance internal validity
Analysis Simple statistical analysis is usually  Complex analysis is required for multi-arm trials and cluster-randomized trials
possible Compliance with the protocol is likely to be of greater interest, and a 
per-protocol analysis may offer information regarding aspects of the 
protocol that did or did not add value 
Trial reporting
Reporting Should follow CONSORT statement Should follow CONSORT statement or the extension relating to cluster-
randomized trials when appropriate
ScvO2 = central venous oxygen saturation; SIRS, Systemic Inflammatory Response Syndrome; CONSORT, Consolidated Standards of Reporting Trials.changed over time (Table 2) all aid in designing a trial. These
studies also provide clinicians with the context within which
the evaluation of the protocol is taking place.
Prospective observational studies and surveys
A prospective observational study may add to the previous
background data, defining current care and the associated
baseline outcome rate. Prospective observational studies may
assist in defining ‘standard care’, determining the appropriate
treatment for the control arm in a future process-of-care trial
and the expected outcomes in the control patients. These
data, combined with a realistic potential treatment effect,
allow investigators to determine an appropriate sample size.
Surveys of clinician opinions may identify potential barriers to
the implementation of the trial intervention. For example, if a
trial required patients with severe sepsis be treated in the
emergency department for six hours but a survey of
emergency physicians revealed that most would not delay
transfer to the ICU, such a trial might not be possible. Both
prospective observational studies and surveys may also
provide information regarding differences in attitudes and
practice between countries.
For cluster-randomized trials (studies that randomize at the
level of the centre rather than the patient), reliable estimates
of practice variability and outcomes differences between
centres are needed. These data can guide the design and
analytic plan by noting variances that must be accounted for
during the analysis.
Pilot studies
Pilot studies, by which we refer to small prospective RCTs
designed to test aspects of the intervention, are vital for
determining the feasibility, reproducibility or implementation
problems associated with the complex intervention evaluated.
Given that existing processes of care will differ between
centres, pilot studies in multiple centres are preferable,
particularly to ensure that a multi-centre trial is feasible in
both academic (for example, tertiary referral) and non-
academic (for example, community and rural) hospitals. For
example, barriers to the training and implementation of a
medical emergency team in a large teaching hospital will be
different to those in smaller community hospitals and pilot
studies may help to identify these issues. This will have
particular importance if a trial is conducted in multiple
countries, when the variation in practice is likely to be greater.
Trial design
All clinical research, including studies of complex inter-
ventions or processes of care, should be designed to answer
a clearly articulated question [16]. This should be a terse
declarative statement or focused question - the former, using
a hypothesis format (research or null) is common and best
expressed clearly. Clinicians will need to consider both the
internal validity (the extent to which systematic error has been
avoided) and the external validity (the extent to which the
results of the trial provides a correct basis for generalization
to other circumstances) [17] to make a judgment about
whether a new complex intervention has a place in their
clinical context.
The population
In most studies of simple interventions, the population under
investigation is a well-defined group of patients with a similar
condition, such as patients with acute myocardial infarction.
Some complex interventions will involve populations with a
defined condition, such as patients with early severe sepsis
[5] or high-risk surgical patients [18]. In other circumstances,
the population under investigation may not be as clear-cut.
The aim of other studies, such as the introduction of trauma
teams [19] or medical emergency teams [4], is to determine
whether changing the overall healthcare system can deliver
improved care. In these cases, the population may be the
healthcare providers or an entire healthcare system. Studies
designed to evaluate whether the process improves
outcomes for individual patients may still randomize individual
patients. However, in studies designed to evaluate how best
to ensure healthcare providers implement a complex protocol,
the unit of randomization for implementing the new protocol
may need to be the healthcare providers, or even whole
hospitals, to avoid contamination of the control group. It is
important to realise that the unit of randomisation, observation
and outcome measurement need not necessarily all be the
same. For example it may be possible to randomize at the
level of the health service provider and measure outcomes in
individual patients.
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Table 2
Crude mortality by calendar year (1997 to 2005) for patients
admitted to ICU following presentation to the emergency
department in Australia and New Zealand with sepsis or septic
shock
Percent ICU mortality  Percent hospital 
Calendar year (n)a mortality (n)b
1997 27.4 (96/351) 35.6 (124/348)
1998 29.1 (87/298) 37.7 (113/301)
1999 22.6 (60/266) 30.7 (80/261)
2000 27.8 (148/534) 35.2 (184/522)
2001 23.3 (196/840) 31.6 (256/809)
2002 21.7 (219/1,011) 28.1 (280/994)
2003 19.7 (241/1,223) 25.8 (311/1,209)
2004 18.5 (260/1,403) 24.9 (350/1,403)
2005 15.6 (207/1,324) 21.2 (281/1,325)
aFor ICU mortality, total number of patients = 7,250 (data not available
for 399 patients (5.2 percent)). bFor hospital mortality, total number of
patients = 7,172 (data not available for 477 patients (6.2 percent).
ICU, intensive care unit. (Reproduced with permission from [15].)The intervention
Care must be exercised to specify exactly what is being
studied. For example, a protocol for the resuscitation of
patients with severe sepsis in the emergency department [5]
includes a number of individual components that could affect
outcome (that is, fluid resuscitation, vasopressors, blood
transfusion, ventilation). Alternatively, it may be the use of a
novel monitoring device or the attention of the additional
support staff necessary to co-ordinate the protocol that
makes a difference. Clearly, any or all of these factors may be
the essential component(s) that contribute to improved
patient outcomes. In early goal-directed sepsis care, the
intervention studied is the total protocol and the team that
identify and alleviate early hypoperfusion. The total inter-
vention may consist of a number of tests (such as the
measurement of serum lactate), measurements (such as the
measurement of central venous oxygen saturation), and
interventions (for example, fluids, dobutamine and blood
transfusions) that are prescribed in response to these
measurements. It may not be possible to determine which
particular part of the intervention is the primary reason for any
observed change in mortality. This lack of clarity may be
frustrating for clinicians who disagree with elements of the
protocol. However, it need not impede rigorous initial
evaluation of the impact of the overall protocol [9]. The
analogy to studies of single interventions is clear; for example,
acceptance of streptomycin as a treatment for tuberculosis
occurred [20] long before a clearly defined molecular
mechanism existed [21]. Similarly, a protocol that reduces
mortality could be implemented with subsequent research
undertaken to identify the component(s) most directly
responsible for the benefit.
Alternatively, the intervention could be a suite of educational
materials designed to improve compliance with a bundle of
measures - for example, efforts to reduce central venous
catheter related blood stream infections. In this case, the
intervention may be an intensive campaign with computerised
order sets, regular audits, standardised checklists and one-
to-one educational sessions to ensure compliance compared
to a less intensive campaign with only a routine checklist. The
optimal approach is determined by the research question that
is being addressed.
Context dependence. New processes of care may have
different impacts on outcome depending on the background
processes already in place. The current care context into which
the new process of care is introduced needs to be considered
to ensure that the proposed intervention will have the
appropriate and desired outcome. For example, a resuscitation
protocol for patients with early severe sepsis tested in a single
centre may not produce results that are generalisable because
of aggressive ancillary care that might be uncommon
elsewhere. Such a protocol may need to be tested in a multi-
centre study that includes various hospital types and locations
to support the generalisability or external validity of the results.
Reproducibility. One of the major challenges in evaluating
new complex interventions is ensuring that the intervention is
accurately and reliably delivered. For large-scale trials, this is
a continuous process. Delivery of the intervention could
potentially improve over time from a ‘learning curve effect’.
Conversely, delivery of the intervention may degrade with
time if the recruitment period is prolonged and trial fatigue
develops. Pilot studies can help identify these learning
curves, with data from the pilot intentionally excluded from the
final analysis and serving only to prepare for the study. It is
likely that a variety of methods will be required to ensure that
the intervention is delivered reliably, including audits, com-
puterized reminders, checklists, intensive one-to-one
educational sessions and incentives for sites with the highest
compliance, which may all ensure smooth implementation of
the set protocols. These must be described so that clinicians
can use (or avoid) strategies when implementing the new
processes in their own practice.
The comparison group
One area of contention when evaluating new complex
interventions or processes of care is how to define the
comparison (control) group. This is a complicated problem
and the optimal approach is unclear [22]. Is the control ‘care
as it happens now’ (termed ‘wild type’) or is it ‘a regimented
and commonly accepted care’? The Acute Respiratory
Distress Network (ARDSNet) low tidal volume trial [23]
generated controversy in defining the comparator [24,25]. In
that trial, it was argued that the control group received a
standardized treatment that substantially differed from usual
clinical practice; the trial results could be interpreted as
demonstrating that a low tidal volume strategy is better than
high tidal volume ventilation in patients with acute lung injury.
This differs from concluding that introducing a protocol for
low tidal volume ventilation reduces mortality when compared
with current practice.
There are a number of ways to address this issue. First, if the
requisite systematic review and observational studies are
complete, researchers will be aware of what is ‘usual’ or
standard care. Second, dual comparison groups may be
included; in the example above, a low tidal volume group, a
structured higher (albeit commonly used) tidal volume group,
and a ‘wild-type’ group where the tidal volume is determined
by the treating clinician would resolve this concern. This
allows those performing the study and clinicians reading the
results to determine whether the new intervention (for
example, the low tidal volume protocol) is superior not only to
the high tidal volume protocol, but also current practice.
The problem with this dual control approach is that the use of
three groups complicates the analysis and increases the
required sample size. Sample size may be kept lower if a
sequential hypothesis testing procedure is used. For example,
one first tests whether a ventilation protocol (either high
volume or low volume) is better than allowing clinicians to
Available online http://ccforum.com/content/12/2/210
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one can then ask if one protocol is superior to the other.
Without meticulous attention to study rationale and ensuring
an adequately powered study, the chance is high that the first
hypothesis test will suggest no difference between thera-
peutic arms, thus precluding further primary hypothesis testing.
An alternative approach may be to have only two groups, that
is, the new process compared to ‘usual care’. This retains the
advantage that the control group receives care titrated by
clinicians in response to changes in patients’ conditions,
rather than applying a protocolized approach (a criticism of
complex therapy trials in the critically ill [26]). This will simplify
the analysis and place less pressure on the required sample
size. If ‘usual care’ differs greatly from country to country or
centre to centre, concerns may be raised that the control arm
is uninterpretable and not representative of ‘usual care’ in
other settings. Also, education and training for the new
process may contaminate the ‘usual care’ control group. As
the trial progresses and more medical and nursing staff are
exposed to the education required to implement the new
process, it is possible that standard care will drift towards
that being implemented in the new process or protocol.
Changes in the outcomes in the control group may be seen
due to these processes even in the absence of the new
intervention, a phenomenon that has been previously observed
(Figure 1) [4]. Thus, differences in care between the groups
will be less than otherwise anticipated, which may also
reduce the apparent treatment effect and the power of the
study, and may require reconsideration of the sample size. It
may also cause some concern among clinicians who perceive
their practice to be considerably different to that delivered in
the ‘usual care’ arm of the trial and, therefore, question the
applicability of the findings to their patients.
The outcome
Choosing a primary outcome for a complex intervention RCT
is no different to choosing an outcome in any clinical
research. The outcome should be robust and well defined to
avoid ascertainment bias. For most trials in critical care, a
clinically important outcome such as all-cause mortality at a
defined point in time, such as 30 or 90 days, is appropriate.
One unique aspect of trials evaluating complex interventions
is the need to collect data concerning the actual process of
care to demonstrate adherence to the protocol. It may not be
possible to measure compliance with every aspect of the
protocol, so decisions will need to be made regarding the
key components of any given protocol. When assessing
compliance with a resuscitation protocol, it may be important
to measure not only that each component of the protocol is
delivered, but also that they are delivered in a timely manner.
For example, in a resuscitation protocol that is guided by the
use of continuous measurement of central venous oxygen
saturation, it may be necessary to ensure that this
measurement is collected in every patient in the treatment
arm, and that it is not used in the control arm of the trial. It
may also be necessary to measure how long it took to
achieve the goals set by the protocol, and how these goals
were achieved. Secondary analyses, regarding which
aspects of the protocol were most often delivered or
neglected, may offer insights into success or failure of the
intervention that may help guide future research projects.
Data collection - especially that focused on adherence to
protocol delivery - must continue throughout the delivery of
the entire process, which has resource implications for
researchers and funding agencies.
Trial execution
Randomization
The randomization process, particularly allocation conceal-
ment (preventing anyone knowing which group an individual
or cluster of patients will be randomized to, until randomiza-
tion occurs), is essential to limit bias [27]. Trials of complex
interventions may differ from trials of simple therapies when
the unit of randomization is whole practice units (for
example, hospitals, ICUs) or individual providers (for
example, for an educational intervention). By randomizing at
the hospital level (cluster randomization), it is less likely that
the educational efforts required to successfully implement
the new process will affect the control group. This approach
has previously been used in trials of complex interventions in
critical care [4,6]. However, heterogeneity between the
various healthcare services may be problematic, with very
large numbers of hospitals (for example, more than 100
units) required to obtain adequate power. Identification and
randomization of large numbers of suitable ICUs or hospitals
may not be logistically feasible or economically viable.
Moreover, cluster randomization does not ensure blinding of
the clinical trial.
Critical Care    Vol 12 No 2 Delaney et al.
Page 6 of 9
(page number not for citation purposes)
Figure 1
MERIT study changes in outcomes over time: control hospitals. Drawn
from data in [4]. ICU, intensive care unit.Blinding
Blinding, defined as attempts to keep trial participants,
investigators or assessors unaware of the assigned treat-
ment, is important to limit bias in clinical trials [28]. It may not
be possible to conduct a RCT evaluating a complex
intervention or process-of-care in a blinded fashion. As
blinding is largely designed to avoid bias in the ascertainment
of outcomes, using clear, robust and well-defined outcomes
can help to limit this concern. If less objective outcomes are
needed in an unblinded trial (such as assessing neurological
recovery using the Glasgow outcome score or diagnosing
the presence of ventilator associated pneumonia), using an
outcome adjudication committee unaware of the intervention
can help avoid bias. Data collectors and data analysts unaware
of the intervention used in each patient can also limit bias.
Analysis
The primary analysis of most trials evaluating complex
interventions does not differ from that of trials involving single
interventions. In particular, while it may be tempting to exclude
patients or centres where the intervention was not fully
implemented, an intention-to-treat analysis (analysing all
participants in the group to which they were randomized,
regardless of whether they completed the protocol or not [10])
is the best primary focus of the results. Differences between
the results of an intention-to-treat analysis and a per-protocol
analysis or additional sensitivity analyses may point to
implementation difficulties and may highlight areas for future
research. If a cluster-randomized design or multiple groups
have been involved, the analysis will necessarily be more
complex and require advanced analytic techniques. For all trials
regardless of design, a pre-analysis statistical plan will ease
concerns of post hoc data manipulation and analytical bias.
Trials of complex interventions lend themselves to subgroup
analyses. By examining each component of a new protocol,
researchers may be able to demonstrate associations
between these components and various outcome measures.
Subgroup analyses should be prospectively determined,
included in a statistical analysis plan, and limited in number
(to avoid an appearance of pre-planned data mining). While
subgroup analyses may help form hypotheses for future
research, they should not be relied upon to provide robust
evidence to guide clinical practice [29,30] and should be
done with extreme caution and with stated clarity if initiated
after data collection (again for concerns of data mining).
Trial reporting
There are widely accepted standards for the reporting of
parallel group RCTs [31] and cluster randomized clinical
trials [32]. These guidelines are equally applicable when
reporting trials of complex interventions. Attention should
focus on the description of the intervention, allowing it to be
reproduced if so desired. A careful description of the
treatments delivered to the control group(s) is needed. This
will allow clinicians to determine the implementation context
and may demonstrate any deviations from usual care that may
have occurred in the control group as a result of the
implementation of the new intervention.
Assessment of the strength of the evidence
for complex interventions
With increasing focus on evidence-based medicine,
considerable attention is paid to the internal validity of
studies. However, while an internally valid study is essential, it
may not be sufficient to warrant a change in clinical practice.
Many factors contribute to understanding the utility of a new
complex intervention. For example, the guidelines proposed
by Sir Austin Bradford Hill in 1965 relating to the
determination of causal associations are important [33].
These include the strength of the association, consistency of
the association in different contexts, the temporal relationship
between the intervention and the outcome, the dose-
response relationship and the underlying biological
plausibility of the intervention. Multiple studies of a complex
intervention may be needed to fully address these issues.
Clinicians may wonder about the inclusion criteria used in a
clinical trial and if this differs from patients in their setting.
Multi-centre studies or methodologically sound observational
studies offer some protection from this concern. Progress in
the treatment of the disease and changes in technology also
need to be considered. These factors may impact on the
existing processes to change mortality over time (as
illustrated in Table 2) and make the interpretation of the data
and predicting the impact of the new interventions more
difficult. Ongoing surveillance may identify other unexpected
untoward consequences arsing from new interventions, such
as changes in antibiotic prescribing leading to changes in
bacterial resistance patterns or outcomes.
Given these difficulties, some attempts to develop simple
grading systems to summarise the strength of evidence in the
medical literature exist [34], none of which is ideal. While
these grading systems are constantly being refined [35],
most clinicians will find the use of a structured critical
appraisal helps them assess the strength of evidence
provided by individual trial reports.
Ongoing research
The challenge of improving the process of care for critically ill
patients will not be overcome by a single research project.
For example, the mortality rates for acute myocardial
infarction have fallen over the past 20 years, not due to a
single intervention, but due to multiple interventions that have
been combined into a process of care that improves overall
outcome [36]. It is not just the percutaneous coronary
intervention that improves outcome, but also the combination
of aspirin, beta-blockers, early recognition by the emergency
medical staff, having a reperfusion team available for early
angiography, ensuring that the appropriate discharge
medications are given and that the patient attends an
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improve outcomes. These interventions are accepted because
of large suitably designed RCTs, which have consistently
shown their effectiveness. The same is likely to be true in
other acute care areas. For example, improvement in the
outcome for patients with severe sepsis may require early
identification, effective resuscitation, early and appropriate
antimicrobial therapy and adequate source control, all
delivered by the appropriate people at the appropriate time.
The results of RCTs of complex critical care interventions
must be examined closely so that an ongoing program of
research aimed at improving the care of the critically ill can be
sustained. Each completed project is likely to suggest
problems that need further investigation. Examples might
include better ways to ensure compliance with a protocol,
refined protocols with more of one component and less of
others, extending the scope of the new process to other
populations or moving the process into a new context, such
as out of academic centres and into community hospitals. By
doing so, all critically ill patients can share in improvements in
the process of their care.
Conclusion
There are specific issues involved in the evaluation of
complex interventions that clinicians should consider. By
considering these details, both researchers and clinicians will
be able to work together to improve the process by which we
care for critically ill patients.
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